Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Debt to Equity (2022 - 2025)

Axsome Therapeutics' Debt to Equity history spans 4 years, with the latest figure at $2.13 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 35.85% year-over-year to $2.13; the TTM value through Dec 2025 reached $2.13, down 35.85%, while the annual FY2025 figure was $2.13, 35.85% down from the prior year.
  • Debt to Equity for Q4 2025 was $2.13 at Axsome Therapeutics, up from $1.73 in the prior quarter.
  • Across five years, Debt to Equity topped out at $6.54 in Q2 2022 and bottomed at $0.64 in Q3 2022.
  • The 4-year median for Debt to Equity is $1.73 (2025), against an average of $2.05.
  • The largest annual shift saw Debt to Equity tumbled 89.96% in 2023 before it surged 243.16% in 2024.
  • A 4-year view of Debt to Equity shows it stood at $0.91 in 2022, then rose by 5.66% to $0.97 in 2023, then soared by 243.16% to $3.31 in 2024, then tumbled by 35.85% to $2.13 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Debt to Equity are $2.13 (Q4 2025), $1.73 (Q3 2025), and $1.73 (Q2 2025).